Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 34.2× Recursion Pharmaceuticals Inc's market cap, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| RXRX | VTIP | |
|---|---|---|
Market Cap | $2.14B | $73.20B |
Volume | 30,789,535 | 2,511,360 |
Sector | Health | — |
52-Week High | $6.79 | $50.46 |
52-Week Low | $2.84 | $48.38 |
Typical Hold Time | 22 Days | 91 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $48.46, showing minimal daily movement with a 0.08% gain. Technical indicators present mixed signals with a bearish overall trend but bullish oscillators. The ETF focuses on short-duration TIPS to hedge inflation while minimizing interest rate sensitivity. Recent institutional buying activity includes NewEdge Advisors increasing their position by 45.5% in Q2 2026.
The ETF offers defensive positioning amid persistent inflation above the Fed's 2% target for 65 consecutive months. While providing inflation protection with reduced duration risk, VTIP faces headwinds from potential Fed policy shifts and competition from other TIPS vehicles. Real yields at multi-decade highs create attractive entry points for inflation-sensitive allocations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
